Shares of Moderna Inc. MRNA dropped 0.31% to $63.94 Tuesday, on what proved to be an all-around favorable trading session for ...

Moderna (MRNA) closed at $63.94 in the latest trading session, marking a -0.31% move from the prior day. This change lagged the S&P 500's 0.25% gain on the day. At the same time, the Dow added 0.2%, ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Moderna’s cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.